edoc

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

O'Connor, P. W. and Goodman, A. and Kappos, L. and Lublin, F. D. and Miller, D. H. and Polman, C. and Rudick, R. A. and Aschenbach, W. and Lucas, N.. (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology, Vol. 76, H. 22. pp. 1858-1865.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006992

Downloads: Statistics Overview

Abstract

Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of patients with multiple sclerosis (MS) despite a lack of data regarding the safety of treatment interruption, the rate and severity of MS disease activity return after treatment interruption, or alternative treatment strategies.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
UniBasel Contributors:Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Lancet Publications
ISSN:0028-3878
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:06 Dec 2013 09:36
Deposited On:06 Dec 2013 09:36

Repository Staff Only: item control page